BioMarin Pharmaceutical Inc. Completes Acquisition of Alesta

What Happened

• BioMarin Pharmaceutical Inc. announced in an 8-K filed Sept. 1, 2026 that it completed the share purchase of Alesta Therapeutics B.V. on August 31, 2026. As a result, Alesta is now a wholly owned subsidiary of BioMarin. The acquisition was made under a Share Purchase Agreement previously disclosed by BioMarin on August 18, 2026.

Key Details

• Transaction completed: August 31, 2026.
• Filing date of this 8-K: September 1, 2026.
• Purchase Agreement previously filed as Exhibit 2.1 to BioMarin’s 8-K on August 18, 2026.
• Other parties named: Alesta Therapeutics B.V., holders listed on Schedule 1.1(a) to the Purchase Agreement, Anaheim SpinCo B.V., and Shareholder Representative Services LLC (as representative).

Why It Matters

• This is a corporate acquisition that changes BioMarin’s corporate structure by bringing Alesta into its consolidated business as a wholly owned subsidiary. Investors should note the completion of the deal and review the previously filed Purchase Agreement for transaction terms and potential impacts. BioMarin may disclose additional financial details, integration plans, or effects on revenue and pipeline in future filings.